Aldomet 250 mg Tablet

Country: Philippines

Language: English

Source: FDA (Food And Drug Administration)

Active ingredient:

Methyldopa

Available from:

Aspen Philippines Inc.; Distributor: Aspen Philippines Inc.

INN (International Name):

Methyldopa

Dosage:

250 mg

Pharmaceutical form:

Tablet

Units in package:

Clear PVC/Alu Foil Blister Pack x 10's (Box of 100's and 500's), Clear PVC/Alu Foil Blisters of 10's (Box of 100's and 500's)

Manufactured by:

Aspen Port Elizabeth (Pty) Ltd., Africa

Authorization date:

2021-02-03

Patient Information leaflet

PHYSICIANS CIRCULAR
METHYLDOPA
ALDOMET
®
250 MG TABLET
Antihypertensive
Methyldopa is an effective antihypertensive agent that reduces both
supine and standing blood pressure. Symptomatic postural
hypotension, exercise hypotension and diurnal blood pressure
variations rarely occur. By adjustment of dosage, morning hypotension
can
be prevented without sacrificing control of afternoon blood pressure.
Methyldopa has no direct effect on cardiac function and usually does
not reduce glomerular filtration rate, renal blood flow, or filtration
fraction. Cardiac output usually is maintained without cardiac
acceleration.
In some patients the heart rate is slowed.
Because of the relative freedom from adverse effects on kidney
function, Methyldopa can be of benefit in the control of high blood
pressure,
even in the presence of renal impairment. It may help arrest or retard
the progression of renal function impairment and damage due to
sustained elevation of blood pressure.
Normal or elevated plasma renin activity may decrease in the course of
Methyldopa therapy.
The ability to inhibit dopa decarboxylase and to deplete animal
tissues of norepinephrine resides solely in the L-isomer (Methyldopa).
In
man, the antihypertensive activity appears to be due solely to the
L-isomer.
PRODUCT DESCRIPTION
A round, biconvex, yellow, film-coated tablet, debossed "ALDOMET" on
one side and "250" on the other side.
FORMULATION
Each tablet contains:
Methyldopa, EP ............................................ 250 mg
INDICATION
Hypertension (mild, moderate or severe).
DOSAGE AND ADMINISTRATION
Oral Therapy
GENERAL CONSIDERATIONS
Methyldopa (Aldomet
®
) is largely excreted by the kidney and patients with impaired renal
function may respond to smaller doses. Syncope in
older patients may be related to an increased sensitivity and advanced
arteriosclerotic vascular disease. This may be avoided by lower doses.
Withdrawal of Methyldopa (Aldomet
®
) is followed by return of hypertension usually within 48 hours. This
is not complicated by an oversho